Valuation
- Market cap
- 488,697,000
- Revenue TTM
- $0
- Net income TTM
- $-59,980,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 794,200
- Avg volume
- 556,594
- Day's range
- $12.59 – $13.24
- Shares out
- 37,621,000
- Stochastic %K
- 72%
- Beta
- 0.86
- Analysts
- Strong Sell
- Price target
- $21.83
Company profile
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain...
Show more
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 333 5280
- Website
- https://www.contineum-tx.com
- Address
- 3565 General Atomics Court, Suite 200, San Diego, United States
Latest news
No headlines yet.
